{
    "root": "9e9485d7-338c-4691-bbe7-37340b176ce8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "XELJANZ",
    "value": "20250306",
    "ingredients": [
        {
            "name": "TOFACITINIB CITRATE",
            "code": "O1FF4DIV0D"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%)",
            "code": "8136Y38GY5"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "CELLULOSE ACETATE",
            "code": "3J2P07GVB6"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "xeljanz/xeljanz xr/xeljanz oral solution janus kinase ( jak ) inhibitor indicated : • rheumatoid arthritis : xeljanz/xeljanz xr indicated treatment adult patients moderately severely active rheumatoid arthritis inadequate response intolerance one tnf blockers . limitations : xeljanz/xeljanz xr combination biologic dmards potent immunosuppressants azathioprine cyclosporine recommended . ( 1.1 ) • psoriatic arthritis : xeljanz/xeljanz xr indicated treatment adult patients active psoriatic arthritis inadequate response intolerance one tnf blockers . limitations : xeljanz/xeljanz xr combination biologic dmards potent immunosuppressants azathioprine cyclosporine recommended . ( 1.2 ) • ankylosing spondylitis : xeljanz/xeljanz xr indicated treatment adult patients active ankylosing spondylitis inadequate response intolerance one tnf blockers . limitations : xeljanz/xeljanz xr combination biologic dmards potent immunosuppressants azathioprine cyclosporine recommended . ( 1.3 ) • ulcerative colitis : xeljanz/xeljanz xr indicated treatment adult patients moderately severely active ulcerative colitis ( uc ) , inadequate response intolerance one tnf blockers . limitations : xeljanz/xeljanz xr combination biological therapies uc potent immunosuppressants azathioprine cyclosporine recommended . ( 1.4 ) • polyarticular course juvenile idiopathic arthritis : xeljanz/xeljanz oral solution indicated treatment active polyarticular course juvenile idiopathic arthritis ( pcjia ) patients 2 years age older inadequate response intolerance one tnf blockers . limitations : xeljanz/xeljanz oral solution combination biologic dmards potent immunosuppressants azathioprine cyclosporine recommended . ( 1.5 )",
    "contraindications": "instructions • xeljanz xr ( tofacitinib extended-release tablets ) interchangeable substitutable xeljanz oral solution . ( 2.1 ) • changes xeljanz xeljanz xr made healthcare provider . ( 2.1 ) • initiate xeljanz/xeljanz xr/xeljanz oral solution absolute lymphocyte count < 500 cells/mm 3 , absolute neutrophil count ( anc ) < 1000 cells/mm 3 hemoglobin < 9 g/dl . ( 2.1 ) recommended rheumatoid arthritis • xeljanz 5 mg twice daily xeljanz xr 11 mg daily . ( 2.2 ) • recommended patients moderate severe renal impairment moderate hepatic impairment xeljanz 5 mg daily . ( 2 , 8.7 , 8.8 ) psoriatic arthritis ( combination nonbiologic dmards ) • xeljanz 5 mg twice daily xeljanz xr 11 mg daily . ( 2.2 ) • recommended patients moderate severe renal impairment moderate hepatic impairment xeljanz 5 mg daily . ( 2 , 8.7 , 8.8 ) ankylosing spondylitis • xeljanz 5 mg twice daily xeljanz xr 11 mg daily . ( 2.2 ) • recommended patients moderate severe renal impairment moderate hepatic impairment xeljanz 5 mg daily . ( 2 , 8.7 , 8.8 ) ulcerative colitis • induction : xeljanz 10 mg twice daily xeljanz xr 22 mg daily 8 weeks ; evaluate patients transition maintenance therapy depending therapeutic response . needed , continue xeljanz 10 mg twice daily xeljanz xr 22 mg daily maximum 16 weeks . discontinue xeljanz 10 mg twice daily xeljanz xr 22 mg daily 16 weeks adequate therapeutic response achieved . ( 2.3 ) • maintenance : xeljanz 5 mg twice daily xeljanz xr 11 mg daily . patients loss response maintenance treatment , xeljanz 10 mg twice daily xeljanz xr 22 mg daily may considered limited shortest duration , careful consideration benefits risks individual patient . lowest effective dose needed maintain response . ( 2.3 ) • adjustment needed patients moderate severe renal impairment moderate hepatic impairment : full prescribing information . ( 2.3 ) polyarticular course juvenile idiopathic arthritis • xeljanz/xeljanz oral solution 5 mg twice daily weight-based equivalent twice daily . ( 2.4 ) • adjustment needed patients moderate severe renal impairment moderate hepatic impairment : full prescribing information . ( 2.4 ) adjustment • full prescribing information adjustments indication patients receiving cyp2c19 and/or cyp3a4 inhibitors ; patients moderate severe renal impairment moderate hepatic impairment ; patients lymphopenia , neutropenia , anemia . ( 2.2 , 2.3 , 2.4 , 8.7 , 8.8 ) • xeljanz/xeljanz xr/xeljanz oral solution patients severe hepatic impairment recommended patient population . ( 2.2 , 2.3 , 2.4 , 8.8 )",
    "warningsAndPrecautions": "supplied information xeljanz/xeljanz xr shown table 22. table 22 : supplied information xeljanz/xeljanz xr bottle size ( number tablets ) ndc number xeljanz 5 mg tofacitinib tablets white , round , immediate-release film-coated tablets , debossed `` pfizer `` one side , `` jki 5 `` side 60 ndc 0069-1001-01 xeljanz 10 mg tofacitinib tablets blue , round , immediate-release film-coated tablets , debossed `` pfizer `` one side , `` jki 10 `` side 60 ndc 0069-1002-01 xeljanz xr 11 mg tofacitinib tablets pink , oval , extended-release film-coated tablets drilled hole one end tablet band `` jki 11 `` printed one side tablet 30 ndc 0069-0501-30 xeljanz xr 22 mg tofacitinib tablets beige , oval , extended-release film-coated tablets drilled hole one end tablet band `` jki 22 `` printed one side tablet 30 ndc 0069-0502-30 supplied information xeljanz oral solution shown table 23. table 23 : supplied information xeljanz oral solution bottle fill ( volume ml ) ndc number xeljanz oral solution 1 mg/ml tofacitinib oral solution clear , colorless solution 240 ml ndc 0069-1029-02",
    "adverseReactions": "none .",
    "indications_original": "XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 )",
    "contraindications_original": "Administration Instructions • XELJANZ XR (tofacitinib extended-release tablets) is not interchangeable or substitutable with XELJANZ Oral Solution. ( 2.1 ) • Changes between XELJANZ and XELJANZ XR should be made by the healthcare provider. ( 2.1 ) • Do not initiate XELJANZ/XELJANZ XR/XELJANZ Oral Solution if absolute lymphocyte count <500 cells/mm 3 , an absolute neutrophil count (ANC) <1000 cells/mm 3 or hemoglobin <9 g/dL. ( 2.1 ) Recommended Dosage Rheumatoid Arthritis • XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. ( 2.2 ) • Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is XELJANZ 5 mg once daily. ( 2 , 8.7 , 8.8 ) Psoriatic Arthritis (in combination with nonbiologic DMARDs) • XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. ( 2.2 ) • Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is XELJANZ 5 mg once daily. ( 2 , 8.7 , 8.8 ) Ankylosing Spondylitis • XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. ( 2.2 ) • Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is XELJANZ 5 mg once daily. ( 2 , 8.7 , 8.8 ) Ulcerative Colitis • Induction: XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily for 8 weeks; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed, continue XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily for a maximum of 16 weeks. Discontinue XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily after 16 weeks if adequate therapeutic response is not achieved. ( 2.3 ) • Maintenance: XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. For patients with loss of response during maintenance treatment, XELJANZ 10 mg twice daily or XELJANZ XR 22 mg once daily may be considered and limited to the shortest duration, with careful consideration of the benefits and risks for the individual patient. Use the lowest effective dose needed to maintain response. ( 2.3 ) • Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment: see full prescribing information. ( 2.3 ) Polyarticular Course Juvenile Idiopathic Arthritis • XELJANZ/XELJANZ Oral Solution 5 mg twice daily or weight-based equivalent twice daily. ( 2.4 ) • Dosage adjustment is needed in patients with moderate and severe renal impairment or moderate hepatic impairment: see full prescribing information. ( 2.4 ) Dosage Adjustment • See the full prescribing information for dosage adjustments by indication for patients receiving CYP2C19 and/or CYP3A4 inhibitors; in patients with moderate or severe renal impairment or moderate hepatic impairment; and patients with lymphopenia, neutropenia, or anemia. ( 2.2 , 2.3 , 2.4 , 8.7 , 8.8 ) • Use of XELJANZ/XELJANZ XR/XELJANZ Oral Solution in patients with severe hepatic impairment is not recommended in any patient population. ( 2.2 , 2.3 , 2.4 , 8.8 )",
    "warningsAndPrecautions_original": "How supplied information for XELJANZ/XELJANZ XR is shown in Table 22.\n                  \n                     Table 22: How Supplied Information for XELJANZ/XELJANZ XR\n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              Bottle Size\n                              \n                              (number of tablets)\n                           \n                           \n                              NDC Number\n                           \n                        \n                     \n                     \n                        \n                           \n                              \n                                 XELJANZ\n                                 \n                                 5 mg tofacitinib tablets\n                                 White, round, immediate-release film-coated tablets, debossed with \"Pfizer\" on one side, and \"JKI 5\" on the other side\n                           \n                           \n                              60\n                           \n                           \n                              NDC 0069-1001-01\n                           \n                        \n                        \n                           \n                              \n                                 XELJANZ\n                                 \n                                 10 mg tofacitinib tablets\n                                 Blue, round, immediate-release film-coated tablets, debossed with \"Pfizer\" on one side, and \"JKI 10\" on the other side\n                           \n                           \n                              60\n                           \n                           \n                              NDC 0069-1002-01\n                           \n                        \n                        \n                           \n                              \n                                 XELJANZ XR\n                                 \n                                 11 mg tofacitinib tablets\n                                 Pink, oval, extended-release film-coated tablets with a drilled hole at one end of the tablet band and \"JKI 11\" printed on one side of the tablet\n                           \n                           \n                              30\n                           \n                           \n                              NDC 0069-0501-30\n                           \n                        \n                        \n                           \n                              \n                                 XELJANZ XR\n                                 \n                                 22 mg tofacitinib tablets\n                                 Beige, oval, extended-release film-coated tablets with a drilled hole at one end of the tablet band and \"JKI 22\" printed on one side of the tablet\n                           \n                           \n                              30\n                           \n                           \n                              NDC 0069-0502-30\n                           \n                        \n                     \n                  \n                  How supplied information for XELJANZ Oral Solution is shown in Table 23.\n                  \n                     Table 23: How Supplied Information for XELJANZ Oral Solution\n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              Bottle Fill\n                              \n                              (volume mL)\n                           \n                           \n                              NDC Number\n                           \n                        \n                     \n                     \n                        \n                           \n                              \n                                 XELJANZ Oral Solution\n                                 \n                                 1 mg/mL tofacitinib oral solution\n                                 Clear, colorless solution\n                           \n                           \n                              240 mL\n                           \n                           \n                              NDC 0069-1029-02",
    "adverseReactions_original": "None."
}